Astellas Pharma buys Xyphos Biosciences, deal worth up to $665 mln

Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition in as many months.